TXN10128 / Txinno Biosci - LARVOL DELTA

First-in-Human Phase 1 Study of TXN10128 (ENPP1i) Plus Irinotecan: Durable Responses in TKI-Refractory EGFR-Mutated NSCLC (IASLC-WCLC 2026) - "These proof-of-concept findings validate the biological rationale for combining ENPP1 inhibition with DNA damage induction to remodel the immunosuppressive TME. Our data supports the further development of TXN10128 in combination with TOP1 inhibitor-based ADCs to maximize the immunological bystander effect and overcome resistance in refractory EGFR-mutated NSCLC."

First-in-human • P1 data • Lung Cancer • Non Small Cell Lung Cancer • Solid Tumor • EGFR • ENPP1 • STING

A Study of TXN10128 in Subjects With Solid Tumors (clinicaltrials.gov) - P1 | N=96 | Recruiting | Sponsor: Txinno Bioscience Inc. | N=36 ➔ 96 | Trial completion date: Aug 2025 ➔ Jun 2026 | Trial primary completion date: Mar 2025 ➔ Dec 2025

Enrollment change • Monotherapy • Trial completion date • Trial primary completion date • Solid Tumor

Preclinical and IND-enabling studies of TXN10128, an ENPP1 inhibitor, for clinical evaluation in patients with solid tumor (SITC 2023) - "Conclusions Together with significant in vivo efficacies in various combination settings and supportive toxicology profile, these studies demonstrated that TXN10128 is a suitable candidate for clinical investigation as a combination partner with existing therapies. Ph I dose escalation study of TXN10128 monotherapy is currently enrolling solid tumor patients in Korea and dose-escalation study of combination therapy will be commencing in near future."

IO biomarker • Preclinical • Oncology • Solid Tumor • CXCL10 • STING • TNFA

A Study of TXN10128 in Subjects With Solid Tumors (clinicaltrials.gov) - P1 | N=36 | Recruiting | Sponsor: Txinno Bioscience Inc. | Not yet recruiting ➔ Recruiting

Enrollment open • Metastases • Oncology • Solid Tumor

A Study of TXN10128 in Subjects With Solid Tumors (clinicaltrials.gov) - P1 | N=36 | Not yet recruiting | Sponsor: Txinno Bioscience Inc.

Metastases • New P1 trial • Oncology • Solid Tumor